Eli Lilly and Company / LLY

Equity | Generated Nov 3, 2026 11:31 PM EST

Current price	Daily move	Bid / Ask	Previous close
$1,410.98	-0.01 0.00%	$1,408.00/$1,413.41	$1,410.99

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Nov 3, 2026 11:31 PM EST**

JW Intelligence Report

Complete | 3 of 3 sections | Nov 3, 2026 6:50 PM EST

JW Rank	Rank label	Confidence	IV percentile
71.2 / 100	Constructive	high	30 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,395.00	$1,485.00	$1,360.00	56 / 100

Options stance	**bullish**
Tail-risk safety	**56 / 100**
JW Rank data coverage / as of	**100.0% | Nov 3, 2026 6:50 PM EST**

Key insight

Lilly's Strong Q3 Results and Raised Guidance Fuel Optimism

Market read

LLY is showing bullish momentum following strong Q3 earnings that beat estimates on both revenue and EPS. The company raised its full-year guidance, citing robust demand for its key products like Mounjaro and Zepbound. Positive news regarding regulatory approvals and pipeline advancements further contribute to the positive sentiment. While the stock trades at a premium valuation, analysts remain optimistic about LLY's long-term growth prospects.

Strategy context

The strong Q3 results and positive outlook suggest continued upside potential for LLY. However, investors should be aware of the elevated valuation and potential risks such as pricing pressure and competition.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Nov 3, 2026 2:15 PM EST**

Short-term scenario

Cautious hold or buy-on-dip over 1-3 weeks. Momentum remains positive after the earnings gap, but overbought RSI and proximity to highs raise the odds of consolidation or a pullback. Prefer scaling in near support rather than chasing strength. Uncertainty is high: a break of recent highs could extend the move, while any profit-taking or broader market weakness could test lower supports quickly.

Three-month outlook

Fundamentals support a constructive bias: Lilly leads the GLP-1 obesity and diabetes market, volume growth has more than offset price declines, guidance was raised substantially, and pipeline items such as retatrutide offer longer-term optionality. Many recent analyst targets were lifted into the $1,500-$1,650 range, though the broader consensus average remains closer to roughly $1,440, implying only modest upside if estimates have not fully caught up. Offsetting risks include the rich valuation, competition (notably Novo Nordisk), ongoing pricing and reimbursement pressure, non-repeating Q3 items, and the possibility of multiple compression if growth decelerates. Technically the stock is extended, so a period of consolidation or a 8-15% retracement is plausible even if the longer-term trend stays intact. Three-month outcomes are uncertain and could range from modest further gains on sustained demand to a deeper pullback on any disappointment or macro risk-off move. This is not a forecast or recommendation.

Market sentiment

Post-earnings X discussion is mostly constructive, citing the beat, guidance raise, GLP-1 demand, Medicare uptake, and analyst actions such as UBS maintaining Buy with a $1,625 target and other raises into the $1,550-$1,650 area. Some posts flag valuation (near 40x adjusted earnings) and price erosion as risks, while options activity has been elevated. Older threads show valuation skepticism. Low-quality promotional posts are common and should be discounted. Sentiment is net positive but tempered by awareness of the sharp rally and premium valuation; social data is noisy and not a reliable forecast.

Supporting evidence


LLY's Q3 earnings report exceeded expectations, with revenue up 39% year-over-year and adjusted EPS beating estimates. | The company raised its full-year revenue guidance by $5-5.5B to $91-92B. | Positive news regarding regulatory approvals and pipeline advancements, including retatrutide head-to-head data versus high-dose Ozempic, boosted investor confidence. | Analyst ratings and price targets have been raised following the earnings release.

Risk watch

LLY's valuation is currently near 40x adjusted earnings, which could make it susceptible to a pullback if growth slows or market sentiment shifts. | Competition in the GLP-1 market from companies like Novo Nordisk remains a key risk factor.

Enhanced price structure


45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
strong_bull	Above MVWAP	Above 200D trend	medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**STRONG BULL | overbought | MACD accelerating**
Trend signal	**STRONG BULL**
RSI signal	**overbought**
RSI (7 / 14 / 21)	**81.50 / 75.80 / 71.45**
RSI velocity	**0.45**
MACD line / signal / histogram	**56.38 / - / 40.27**
MACD acceleration	**5.81**
Stochastic K / D	**85.51 / 85.92**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Above institutional MVWAP | Accumulation bias**
Institutional flow	**16.08**
20-day MVWAP	**$1,292.28**
Price vs 20-day MVWAP	**+9.19%**
Daily reference VWAP	**$1,413.28**
Price vs daily reference	**-0.16%**
Volume	**1.54M**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Positive macro velocity**
Macro velocity	**13.24**
20-day / 200-day SMA	**$1,272.00 / $1,094.99**
Bollinger range	**$1,111.57 - $1,432.43**
Bollinger position	**0.928**

Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
24 / 100	24 / 100	107.63	152.78

Market regime	**Calm**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**backwardation**
Term slope	**-5.94 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 3, 2026 2:53 PM EST**
Options data quality	**Coverage 100.0%**

Option term structure

ATM implied-volatility curve by days to expiration




EXPIRATION	DTE	ATM IV	STATE
2026-11-06	3	40.7%	-
2026-11-13	10	36.2%	-
2026-11-20	17	34.8%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference


Short $1,385.00 | Long $1,380.00 | Width $5.00 | Net credit $1.20



Max profit $120.00 | Max loss -$380.00 | Break-even $1,383.80 | Per contract at expiry

Bear Call Spread reference

Short $1,455.00 | Long $1,460.00 | Width $5.00 | Net credit $1.63



Max profit $163.00 | Max loss -$337.00 | Break-even $1,456.63 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**elevated**
Event IV premium	**4.54**
VIX	**20.77**
VVIX	**107.63**
SKEW index	**152.78**
Observation confidence	**high**
Option quote quality	**reliable**

Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts observed	**114**
Contracts with quotes	**114**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

LLY is showing bullish momentum following strong Q3 earnings that beat estimates on both revenue and EPS. The company raised its full-year guidance, citing robust demand for its key products like Mounjaro and Zepbound. Positive news regarding regulatory approvals and pipeline advancements further contribute to the positive sentiment. While the stock trades at a premium valuation, analysts remain optimistic about LLY's long-term growth prospects.

Options context

Lilly's Strong Q3 Results and Raised Guidance Fuel Optimism

Wheel context

The strong Q3 results and positive outlook suggest continued upside potential for LLY. However, investors should be aware of the elevated valuation and potential risks such as pricing pressure and competition.

Observed evidence

LLY's Q3 earnings report exceeded expectations, with revenue up 39% year-over-year and adjusted EPS beating estimates. | The company raised its full-year revenue guidance by $5-5.5B to $91-92B. | Positive news regarding regulatory approvals and pipeline advancements, including retatrutide head-to-head data versus high-dose Ozempic, boosted investor confidence. | Analyst ratings and price targets have been raised following the earnings release.

Principal risks to monitor

LLY's valuation is currently near 40x adjusted earnings, which could make it susceptible to a pullback if growth slows or market sentiment shifts. | Competition in the GLP-1 market from companies like Novo Nordisk remains a key risk factor.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
$1.33T	**48.35**
ROE	Revenue growth
83.7%	**31.7%**
EPS growth	Operating margin
49.3%	**40.3%**
Net profit margin	Gross margin
31.9%	**-**
Free cash flow CAGR	Debt / equity
5.9%	**1.60**
Dividend yield	Beta
0.8%	**0.39**

52-week range

$812.25 - $1,449.68

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Company	**NYSE**
Industry	Country
Pharmaceuticals	**US**
Currency	IPO date
USD	**1970-07-09**
Shares outstanding	52-week return
940.75M	**67.9%**
Book value per share	Revenue per share
$42.79	**$96.78**

Website	**lilly.com**

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Oct 30, 2026 10:42 AM EDT

Covered Call | 2026-11-06

At signal $1,426.48 | Current $1,410.98

SHORT **Option $1,400.00 B $43.85 / A $48.90**

Conservative | CR $46.38

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$44.49**
ATR as % of price	**3.2%**
Volatility environment	**medium**
Current IV	**32.7%**
IV rank	**27 / 100**
IV percentile	**30 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Nov 3, 2026 6:31 PM EST**

Technical health and risk radar

Derived indicator health and event context

Overall health	**72 / 100**
Trend health	**92 / 100**
Momentum health	**63 / 100**
Volatility health	**63 / 100**
Structure health	**57 / 100**
Earnings risk / date	**unknown | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**medium**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,272.00 / $1,203.50 / $1,094.99**
EMA (9 / 21)	**$1,349.43 / $1,288.95**
Bollinger upper / middle / lower	**$1,432.43 / $1,272.00 / $1,111.57**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.928**
True high / low	**$1,437.00 / $1,393.47**
5-day true high / low	**$1,449.68 / $1,260.34**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	13.241	**-**
SMA50	3.275	**-**
MVWAP20	16.081	**-**
MACD	5.807	**-**
RSI	0.454	**-**
Volume	-286922.330	**-**
ATR	0.654	**-**
T1	-	**52.81 / 1280.17 / 1421.99 / 1382.02**
T2	-	**47.32 / 1264.07 / 1449.68 / 1373.70**
T3	-	**38.96 / 1244.03 / 1408.38 / 1288.30**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,417.94**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Nov 3, 2026 2:53 PM EST**
Options data coverage	**100.0%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX FLAT**
Front expiration / DTE	**2026-11-06 | 3 DTE**
Front at-the-money IV	**40.7%**
25-delta skew	**2.55**
Put / Call 25-delta	**$1,385.00 Delta -0.262 / $1,455.00 Delta 0.251**
Median option bid/ask spread	**18.2%**
Bid/ask spread	**-**
Contracts observed / quoted	**114 / 114**

Price context

Last Price: 1,417.94 | Bid: 1,417.42 | Ask: 1,418.15 | Previous Close: 1,410.99 | Change: 6.95 | Daily change: 0.49% | Update Time: 2026-11-03T14:54:00.435099-05:00 | Latest History Date: 2026-11-03 | Latest History Price: 1,417.68

Historical context

Trading-day sample: 60 sessions | First Date: 2026-08-11 | Latest Date: 2026-11-03 | Latest Price: 1,417.68 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 32.07% | Iv Rank: 23.62 | Iv Percentile: 23.90 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-11-12

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Nov 3, 2026 11:31 PM EST. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**